AU2019273664B2 - Methods for the treatment of psoriatic arthritis - Google Patents

Methods for the treatment of psoriatic arthritis Download PDF

Info

Publication number
AU2019273664B2
AU2019273664B2 AU2019273664A AU2019273664A AU2019273664B2 AU 2019273664 B2 AU2019273664 B2 AU 2019273664B2 AU 2019273664 A AU2019273664 A AU 2019273664A AU 2019273664 A AU2019273664 A AU 2019273664A AU 2019273664 B2 AU2019273664 B2 AU 2019273664B2
Authority
AU
Australia
Prior art keywords
treatment
patient
compound
score
psoriatic arthritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019273664A
Other languages
English (en)
Other versions
AU2019273664A1 (en
Inventor
Pille HARRISON
Luc MEULENERS
Chantal Thérèse Tasset
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfasigma SpA
Original Assignee
Alfasigma SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfasigma SpA filed Critical Alfasigma SpA
Publication of AU2019273664A1 publication Critical patent/AU2019273664A1/en
Assigned to ALFASIGMA S.P.A. reassignment ALFASIGMA S.P.A. Request for Assignment Assignors: GALAPAGOS NV
Application granted granted Critical
Publication of AU2019273664B2 publication Critical patent/AU2019273664B2/en
Priority to AU2025202777A priority Critical patent/AU2025202777A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019273664A 2018-05-24 2019-05-23 Methods for the treatment of psoriatic arthritis Active AU2019273664B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025202777A AU2025202777A1 (en) 2018-05-24 2025-04-22 Methods for the treatment of psoriatic arthritis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1808575.3A GB201808575D0 (en) 2018-05-24 2018-05-24 Methods for the treatment of psoriatic arthrits
GB1808575.3 2018-05-24
PCT/EP2019/063283 WO2019224283A1 (en) 2018-05-24 2019-05-23 Methods for the treatment of psoriatic arthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025202777A Division AU2025202777A1 (en) 2018-05-24 2025-04-22 Methods for the treatment of psoriatic arthritis

Publications (2)

Publication Number Publication Date
AU2019273664A1 AU2019273664A1 (en) 2021-01-21
AU2019273664B2 true AU2019273664B2 (en) 2025-01-23

Family

ID=62812304

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019273664A Active AU2019273664B2 (en) 2018-05-24 2019-05-23 Methods for the treatment of psoriatic arthritis
AU2025202777A Pending AU2025202777A1 (en) 2018-05-24 2025-04-22 Methods for the treatment of psoriatic arthritis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025202777A Pending AU2025202777A1 (en) 2018-05-24 2025-04-22 Methods for the treatment of psoriatic arthritis

Country Status (10)

Country Link
US (2) US12329758B2 (cg-RX-API-DMAC7.html)
EP (1) EP3801548A1 (cg-RX-API-DMAC7.html)
JP (3) JP2021524472A (cg-RX-API-DMAC7.html)
KR (1) KR102955500B1 (cg-RX-API-DMAC7.html)
CN (1) CN112203660B (cg-RX-API-DMAC7.html)
AU (2) AU2019273664B2 (cg-RX-API-DMAC7.html)
CA (1) CA3101386A1 (cg-RX-API-DMAC7.html)
GB (1) GB201808575D0 (cg-RX-API-DMAC7.html)
MA (1) MA52738A (cg-RX-API-DMAC7.html)
WO (1) WO2019224283A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
AU2021308574A1 (en) * 2020-07-13 2023-03-09 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-IL23 specific antibody
EP4287299A4 (en) 2021-01-29 2025-01-01 LG Chem, Ltd. ELECTRODE
EP4305062A1 (en) 2021-03-12 2024-01-17 Janssen Biotech, Inc. Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2445911A1 (en) * 2009-06-26 2012-05-02 Galapagos N.V. 5-phenyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl carboxamides as jak inhibitors
WO2013189771A1 (en) * 2012-06-22 2013-12-27 Galapagos Nv Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
WO2015117980A1 (en) * 2014-02-07 2015-08-13 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
WO2016165953A1 (en) * 2015-04-13 2016-10-20 Galapagos Nv Methods for the treatment of inflammatory disorders
US20170173034A1 (en) * 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1156037B1 (en) 1999-01-29 2004-12-01 Chugai Seiyaku Kabushiki Kaisha Chondrongenesis promotors and indolin-2-one derivatives
US20040138285A1 (en) 2001-04-27 2004-07-15 Makoto Okazaki Chondrogenesis promoters
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
WO2004039816A1 (ja) 2002-10-29 2004-05-13 Shionogi & Co., Ltd. セフェム化合物の無機酸塩の結晶
EP1601672B1 (en) 2003-02-14 2006-07-26 Pfizer Products Inc. Triazolo-pyridines as anti-inflammatory compounds
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
US20070004658A1 (en) 2004-06-21 2007-01-04 Nick Vandeghinste Method and means for treatment of osteoarthritis
MX2007002050A (es) 2004-08-18 2007-03-29 Pharmacia & Upjohn Co Llc Compuestos de triazolopiridina.
EP1799680A2 (en) 2004-10-07 2007-06-27 Warner-Lambert Company LLC Triazolopyridine derivatives as antibacterial agents
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
JP5336375B2 (ja) 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
JP5352476B2 (ja) 2007-06-05 2013-11-27 武田薬品工業株式会社 キナーゼ阻害剤としての二環式複素環化合物
CN101801966A (zh) 2007-07-18 2010-08-11 诺瓦提斯公司 双环杂芳基化合物和它们作为激酶抑制剂的用途
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
CA2691448A1 (en) 2007-08-31 2009-03-05 Dominique Swinnen Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
PE20110063A1 (es) 2008-06-20 2011-02-16 Genentech Inc DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010186A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
US20110124692A1 (en) 2008-07-31 2011-05-26 Daiichi Sankyo Company, Limited Crystalline forms of thiazolidinedione compound and its manufacturing method
JP2013049632A (ja) 2011-08-30 2013-03-14 Kowa Co ベンゾチアジン化合物のモノマレイン酸塩を有効成分とするアレルギー疾患の予防及び/又は治療剤
SA112330992B1 (ar) 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
SMT202300328T1 (it) 2015-04-13 2023-11-13 Galapagos Nv Metodi per il trattamento di disturbi cardiovascolari
FI3595667T3 (fi) * 2017-03-14 2024-01-12 Galapagos Nv Farmaseuttiset koostumukset, joihin sisältyy jak-estäjän tausta

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2445911A1 (en) * 2009-06-26 2012-05-02 Galapagos N.V. 5-phenyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl carboxamides as jak inhibitors
WO2013189771A1 (en) * 2012-06-22 2013-12-27 Galapagos Nv Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
WO2015117980A1 (en) * 2014-02-07 2015-08-13 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
WO2016165953A1 (en) * 2015-04-13 2016-10-20 Galapagos Nv Methods for the treatment of inflammatory disorders
US20170173034A1 (en) * 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROBIN-JAGERSCHMIDT, C. et al. "THE JAK1 SELECTIVE INHIBITOR FILGOTINIB REGULATES BOTH ENTHESIS AND COLON INFLAMMATION IN A MOUSE MODEL OF PSORIATIC ARTHRITIS" ANNALS OF THE RHEUMATIC DISEASES, vol. 76, no. Suppl. 2, June 2017, pages 118-119 *

Also Published As

Publication number Publication date
WO2019224283A1 (en) 2019-11-28
US20260108530A1 (en) 2026-04-23
JP7751362B2 (ja) 2025-10-08
CA3101386A1 (en) 2019-11-28
AU2025202777A1 (en) 2025-05-08
EP3801548A1 (en) 2021-04-14
JP2021524472A (ja) 2021-09-13
JP2024069223A (ja) 2024-05-21
MA52738A (fr) 2021-04-14
AU2019273664A1 (en) 2021-01-21
JP2025183397A (ja) 2025-12-16
US12329758B2 (en) 2025-06-17
US20210299135A1 (en) 2021-09-30
KR102955500B1 (ko) 2026-04-21
CN112203660B (zh) 2024-12-31
KR20210013168A (ko) 2021-02-03
GB201808575D0 (en) 2018-07-11
CN112203660A (zh) 2021-01-08

Similar Documents

Publication Publication Date Title
AU2025202777A1 (en) Methods for the treatment of psoriatic arthritis
US11993605B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US20220267342A1 (en) PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11524964B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US20220251105A1 (en) Methods of treating a mk2-mediated disorder
US20190314382A1 (en) Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
JP2023542878A (ja) 多発性硬化症を治療するためのlou064
JP2018154648A (ja) Il−4rアンタゴニストを投与することによるアトピー性皮膚炎を処置するための方法
US11780848B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
Zhao et al. The off-label uses profile of tofacitinib in systemic rheumatic diseases
Baraf et al. LB0002 SAFETY & EFFICACY OF SEL-212 IN PATIENTS WITH GOUT REFRACTORY TO COVENTIONAL TREATMENT: OUTCOMES FROM TWO RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE III STUDIES
TW202126329A (zh) 使用白細胞介素-17(il-17)拮抗劑治療自體免疫性疾病之方法
JP2022549379A (ja) ウパダシチニブによる脊椎関節炎及び乾癬状態の治療
Chaplin Janus kinase inhibitors for autoimmune disorders
US12570664B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Zhang et al. Preclinical characterization of the selective Jak1 inhibitor Lw402 for treatment of rheumatoid arthritis
Hawkins 54 Rheumatoid Arthritis and Osteoarthritis
CN115364230A (zh) 一种药物组合物以及其在难治性类风湿关节炎治疗方面的应用

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ALFASIGMA S.P.A.

Free format text: FORMER APPLICANT(S): GALAPAGOS NV

FGA Letters patent sealed or granted (standard patent)